Home   |   Press   |   Contact   |   Sitemap   

Cenix BioScience GmbH, Dresden

Cenix BioScience is a Heidelberg spin-off of the Max-Planck-Institute for Cell and Molecular Biology. The company is a pioneer in the field of RNAi (RNA interference), an area that was named "breakthrough of the year 2002" by Science magazine. This area promises to deliver an entirely new class of therapeutic molecules, which are likely to address targets that are not "druggable" by classical therapeutic agents, and which can be designed for extraordinary specificity. Cenix BioScience is a pure play service business that provides research tools and services to the reagents industry and to academia.

Cenix BioScience is a seed investment of Heidelberg Innovation BSV I. Heidelberg Innovation BSV II participated in the last financing round in 2002. The company has been cash break even since then.

- Dr. Christophe J. Eccheverri (CEO)

Investment Manager:
- Dr. Christoph Kronabel (Advisory Board)

Weitere Investoren:
- EMBL Technology Fund
- K/S Danish Bioventure
- TechnoStart